000156801 001__ 156801
000156801 005__ 20240229123116.0
000156801 0247_ $$2doi$$a10.1158/1055-9965.EPI-19-1527
000156801 0247_ $$2pmid$$apmid:32581112
000156801 0247_ $$2ISSN$$a1055-9965
000156801 0247_ $$2ISSN$$a1538-7755
000156801 0247_ $$2altmetric$$aaltmetric:84630455
000156801 037__ $$aDKFZ-2020-01118
000156801 041__ $$aeng
000156801 082__ $$a610
000156801 1001_ $$00000-0002-5025-4709$$aHuynh-Le, Minh-Phuong$$b0
000156801 245__ $$aA genetic risk score to personalize prostate cancer screening, applied to population data.
000156801 260__ $$aPhiladelphia, Pa.$$bAACR$$c2020
000156801 3367_ $$2DRIVER$$aarticle
000156801 3367_ $$2DataCite$$aOutput Types/Journal article
000156801 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1600331389_28430
000156801 3367_ $$2BibTeX$$aARTICLE
000156801 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000156801 3367_ $$00$$2EndNote$$aJournal Article
000156801 500__ $$a2020 Sep;29(9):1731-1738
000156801 520__ $$aA polygenic hazard score (PHS)-the weighted sum of 54 SNP genotypes-was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we assess the potential impact of PHS-informed screening.UK population incidence data (Cancer Research UK) and data from the Cluster Randomized Trial of PSA Testing for Prostate Cancer were combined to estimate age-specific clinically significant prostate cancer incidence (Gleason≥7, stage T3-T4, PSA ≥10, or nodal/distant metastases). Using hazard ratios estimated from the ProtecT prostate cancer trial, age-specific incidence rates were calculated for various PHS risk percentiles. Risk-equivalent age-when someone with a given PHS percentile has prostate cancer risk equivalent to an average 50-year-old man (50-years-standard risk)-was derived from PHS and incidence data. Positive predictive value (PPV) of PSA testing for clinically significant prostate cancer was calculated using PHS-adjusted age groups.The expected age at diagnosis of clinically significant prostate cancer differs by 19 years between the 1st and 99th PHS percentiles: men with PHS in the 1st and 99th percentiles reach the 50-years-standard risk level at ages 60 and 41, respectively. PPV of PSA was higher for men with higher PHS-adjusted age.PHS provides individualized estimates of risk-equivalent age for clinically significant prostate cancer. Screening initiation could be adjusted by a man's PHS.Personalized genetic risk assessments could inform prostate cancer screening decisions.
000156801 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000156801 588__ $$aDataset connected to CrossRef, PubMed,
000156801 7001_ $$aFan, Chun Chieh$$b1
000156801 7001_ $$aKarunamuni, Roshan$$b2
000156801 7001_ $$00000-0001-7696-3661$$aWalsh, Eleanor I$$b3
000156801 7001_ $$00000-0003-2575-387X$$aTurner, Emma L$$b4
000156801 7001_ $$00000-0003-4581-9346$$aLane, J Athene$$b5
000156801 7001_ $$00000-0002-7992-7719$$aMartin, Richard M$$b6
000156801 7001_ $$00000-0002-6033-5086$$aNeal, David E$$b7
000156801 7001_ $$00000-0002-6488-5472$$aDonovan, Jenny L$$b8
000156801 7001_ $$aHamdy, Freddie C$$b9
000156801 7001_ $$aParsons, J Kellogg Kellogg$$b10
000156801 7001_ $$00000-0002-3698-6241$$aEeles, Rosalind A$$b11
000156801 7001_ $$aEaston, Douglas F$$b12
000156801 7001_ $$aKote-Jarai, Zsofia$$b13
000156801 7001_ $$00000-0002-7178-3431$$aAmin Al Olama, Ali$$b14
000156801 7001_ $$aBenlloch Garcia, Sara$$b15
000156801 7001_ $$00000-0001-6429-988X$$aMuir, Kenneth$$b16
000156801 7001_ $$00000-0002-1073-2753$$aGrönberg, Henrik$$b17
000156801 7001_ $$00000-0002-4623-0544$$aWiklund, Fredrik$$b18
000156801 7001_ $$aAly, Markus$$b19
000156801 7001_ $$00000-0002-1863-0305$$aSchleutker, Johanna$$b20
000156801 7001_ $$aSipeky, Csilla$$b21
000156801 7001_ $$aTammela, Teuvo$$b22
000156801 7001_ $$aNordestgaard, Børge Grønne$$b23
000156801 7001_ $$00000-0003-2294-307X$$aKey, Timothy J$$b24
000156801 7001_ $$00000-0002-9571-0763$$aTravis, Ruth C$$b25
000156801 7001_ $$00000-0001-8494-732X$$aPharoah, Paul D P$$b26
000156801 7001_ $$00000-0003-0843-2468$$aPashayan, Nora$$b27
000156801 7001_ $$aKhaw, Kay-Tee$$b28
000156801 7001_ $$aThibodeau, Stephen N$$b29
000156801 7001_ $$aMcDonnell, Shannon K$$b30
000156801 7001_ $$aSchaid, Daniel J$$b31
000156801 7001_ $$aMaier, Christiane$$b32
000156801 7001_ $$aVogel, Walther$$b33
000156801 7001_ $$aLuedeke, Manuel$$b34
000156801 7001_ $$00000-0002-0339-3394$$aHerkommer, Kathleen$$b35
000156801 7001_ $$aKibel, Adam S$$b36
000156801 7001_ $$aCybulski, Cezary$$b37
000156801 7001_ $$aWokolorczyk, Dominika$$b38
000156801 7001_ $$aKluzniak, Wojciech$$b39
000156801 7001_ $$00000-0003-2602-3668$$aCannon-Albright, Lisa A$$b40
000156801 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b41$$udkfz
000156801 7001_ $$0P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aSchöttker, Ben$$b42$$udkfz
000156801 7001_ $$aHolleczek, Bernd$$b43
000156801 7001_ $$aPark, Jong Y$$b44
000156801 7001_ $$aSellers, Thomas A$$b45
000156801 7001_ $$00000-0002-3307-5549$$aLin, Hui-Yi$$b46
000156801 7001_ $$aSlavov, Chavdar Kroumov$$b47
000156801 7001_ $$aKaneva, Radka P$$b48
000156801 7001_ $$aMitev, Vanio I$$b49
000156801 7001_ $$aBatra, Jyotsna$$b50
000156801 7001_ $$aClements, Judith A$$b51
000156801 7001_ $$00000-0003-1337-7897$$aSpurdle, Amanda B$$b52
000156801 7001_ $$00000-0002-4896-5982$$aTeixeira, Manuel R$$b53
000156801 7001_ $$aPaulo, Paula$$b54
000156801 7001_ $$aMaia, Sofia$$b55
000156801 7001_ $$aPandha, Hardev$$b56
000156801 7001_ $$00000-0002-7262-6227$$aMichael, Agnieszka$$b57
000156801 7001_ $$00000-0001-5347-5083$$aMills, Ian G$$b58
000156801 7001_ $$aAndreassen, Ole A$$b59
000156801 7001_ $$aDale, Anders M$$b60
000156801 7001_ $$00000-0002-4089-7399$$aSeibert, Tyler M$$b61
000156801 773__ $$0PERI:(DE-600)2036781-8$$a10.1158/1055-9965.EPI-19-1527$$gp. cebp.1527.2019 -$$n9$$p1731-1738$$tCancer epidemiology, biomarkers & prevention$$v29$$x1538-7755$$y2020
000156801 909CO $$ooai:inrepo02.dkfz.de:156801$$pVDB
000156801 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b41$$kDKFZ
000156801 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c67a12496b8aac150c0eef888d808d46$$aDeutsches Krebsforschungszentrum$$b42$$kDKFZ
000156801 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000156801 9141_ $$y2020
000156801 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-01-17
000156801 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bCANCER EPIDEM BIOMAR : 2018$$d2020-01-17
000156801 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000156801 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000156801 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000156801 980__ $$ajournal
000156801 980__ $$aVDB
000156801 980__ $$aI:(DE-He78)C070-20160331
000156801 980__ $$aI:(DE-He78)C120-20160331
000156801 980__ $$aI:(DE-He78)HD01-20160331
000156801 980__ $$aUNRESTRICTED